{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:29:34Z","timestamp":1792718974313,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004357","name":"Procter and Gamble","doi-asserted-by":"publisher","award":["P&GP Germany"],"award-info":[{"award-number":["P&GP Germany"]}],"id":[{"id":"10.13039\/100004357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004357","name":"Procter and Gamble","doi-asserted-by":"publisher","award":["PI Prof. Hadji"],"award-info":[{"award-number":["PI Prof. Hadji"]}],"id":[{"id":"10.13039\/100004357","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Poor adherence to oral bisphosphonate therapy remains a major challenge in the treatment of osteoporosis, substantially reducing therapeutic efficacy. While reminder interventions have been proposed as a method to enhance adherence, evidence remains limited. This study aimed to evaluate the impact of written and verbal reminders on medication adherence compared to standard patient care over a 12-month period in a real-world clinical setting. In this randomized controlled study, 180 postmenopausal women diagnosed with osteoporosis were assigned to one of three groups: standard care (control), written reminder, or verbal reminder. Interventions were administered at five standardized time points. Adherence was defined as intake of \u226580% of prescribed weekly doses (\u226542 out of 52 doses) and a \u226535% reduction in serum C-terminal telopeptide of type I collagen (CTX) levels from baseline to 12\u00a0months. No significant differences in adherence rates were observed between groups: 53.2% in the control group, 52.0% in the written reminder group, and 52.7% in the verbal reminder group (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20090.014;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.993). Changes in bone mineral density and serum CTX levels were also comparable across groups. The implementation of standardized written or verbal reminder strategy did not result in a statistically significant improvement in adherence to oral bisphosphonate therapy. Further studies are needed to investigate the reasons for low adherence to treatment.\n                  <\/jats:p>","DOI":"10.1007\/s00223-025-01405-6","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:13:23Z","timestamp":1752689603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of A Patient Reminder Program on Adherence in Postmenopausal Women with Osteoporosis Receiving Oral Bisphosphonate Treatment: A Randomized Clinical Control Trial"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1032","authenticated-orcid":false,"given":"U.","family":"Stumpf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kyvernitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Horas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"1405_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11657-024-01380-9","volume":"19","author":"P Hadji","year":"2024","unstructured":"Hadji P, Esterberg E, Oberm\u00fcller D, Bartsch R (2024) Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Arch Osteoporos 19:26. https:\/\/doi.org\/10.1007\/s11657-024-01380-9","journal-title":"Arch Osteoporos"},{"key":"1405_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008. https:\/\/doi.org\/10.1007\/s00198-004-1652-z","journal-title":"Osteoporos Int"},{"key":"1405_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/archinte.163.17.2052","volume":"163","author":"SE Andrade","year":"2003","unstructured":"Andrade SE, Majumdar SR, Chan KA, Buist DSM, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052. https:\/\/doi.org\/10.1001\/archinte.163.17.2052","journal-title":"Arch Intern Med"},{"key":"1405_CR4","volume-title":"Cochrane database of systematic reviews","author":"A Cranney","year":"2003","unstructured":"Cranney A, Adachi J, Guyatt G, Papaioannou A, Robinson V, Shea B, Tugwell P, Waldegger L, Weaver B, Wells G, Zytaruk N (2003) Risedronate for the prevention and treatment of postmenopausal osteoporosis. In: Cranney A (ed) Cochrane database of systematic reviews. Wiley, Chichester"},{"key":"1405_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.5414\/CP201931","volume":"51","author":"P Hadji","year":"2013","unstructured":"Hadji P, Klein S, H\u00e4ussler B, Kless T, Linder R, Rowinski-Jablokow M, Verheyen F, Gothe H (2013) The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 51:868\u2013872. https:\/\/doi.org\/10.5414\/CP201931","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"1405_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.36518\/2689-0216.1513","volume":"4","author":"TH Mir","year":"2023","unstructured":"Mir TH (2023) Adherence versus compliance. HCA Healthc J Med. 4(2):219\u2013220. https:\/\/doi.org\/10.36518\/2689-0216.1513","journal-title":"HCA Healthc J Med."},{"issue":"4","key":"1405_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2125.2007.02893.x","volume":"63","author":"JK Aronson","year":"2007","unstructured":"Aronson JK (2007) Compliance, concordance, adherence. Br J Clin Pharmacol 63(4):383\u2013384. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02893.x","journal-title":"Br J Clin Pharmacol"},{"key":"1405_CR8","unstructured":"World Health Organization (2003) Adherence to long-term therapies\u202f: evidence for action. https:\/\/iris.who.int\/handle\/10665\/42682"},{"key":"1405_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1046\/j.1365-2850.2002.00474.x","volume":"9","author":"R Gray","year":"2002","unstructured":"Gray R, Wykes T, Gournay K (2002) From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs 9:277\u2013284. https:\/\/doi.org\/10.1046\/j.1365-2850.2002.00474.x","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"1405_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741\u2013753. https:\/\/doi.org\/10.1007\/s00198-010-1335-x","journal-title":"Osteoporos Int"},{"key":"1405_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00393-006-0092-x","volume":"65","author":"WJ Fassbender","year":"2006","unstructured":"Fassbender WJ, Stumpf UC (2006) DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis? Z Rheumatol 65:364\u2013366, 368\u2013369","journal-title":"Z Rheumatol"},{"key":"1405_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1210\/jc.2003-030501","volume":"89","author":"JA Clowes","year":"2004","unstructured":"Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117\u20131123. https:\/\/doi.org\/10.1210\/jc.2003-030501","journal-title":"J Clin Endocrinol Metab"},{"key":"1405_CR13","doi-asserted-by":"crossref","unstructured":"Haynes R, McDonald H, Garg A, Montague P (2002) Interventions for helping patients to follow prescriptions for medications. In: Cochrane Database of Systematic Reviews. Wiley, Chichester","DOI":"10.1002\/14651858.CD000011"},{"key":"1405_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176:182\u2013195. https:\/\/doi.org\/10.7326\/M22-0684","journal-title":"Ann Intern Med"},{"key":"1405_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11657-020-00800-w","volume":"15","author":"P Hadji","year":"2020","unstructured":"Hadji P, Hardtstock F, Wilke T, Joeres L, Toth E, M\u00f6ckel L, Gille P (2020) Estimated epidemiology of osteoporosis diagnoses and osteoporosis-related high fracture risk in Germany: a German claims data analysis. Arch Osteoporos 15:127. https:\/\/doi.org\/10.1007\/s11657-020-00800-w","journal-title":"Arch Osteoporos"},{"key":"1405_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jbmr.5650140212","volume":"14","author":"RGG Russell","year":"1999","unstructured":"Russell RGG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 14:53\u201365. https:\/\/doi.org\/10.1002\/jbmr.5650140212","journal-title":"J Bone Miner Res"},{"key":"1405_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115336","volume":"136","author":"A Fontalis","year":"2020","unstructured":"Fontalis A, Eastell R (2020) The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone 136:115336. https:\/\/doi.org\/10.1016\/j.bone.2020.115336","journal-title":"Bone"},{"key":"1405_CR18","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML, Bruy\u00e8re O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S, Gasparik A, Herrmann M, Jorgensen NR, Kanis J, Kaufman J-M, Laslop A, Locquet M, Matijevic R, McCloskey E, Minisola S, Pikner R, Reginster J-Y, Rizzoli R, Szulc P, Vlaskovska M, Cavalier E (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther 36:2811\u20132824. https:\/\/doi.org\/10.1007\/s12325-019-01063-9","journal-title":"Adv Ther"},{"key":"1405_CR19","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.2147\/PPA.S118396","volume":"10","author":"P Hadji","year":"2016","unstructured":"Hadji P, Jacob L, Kostev K (2016) Gender- and age-related treatment compliance in patients with osteoporosis in Germany. Patient Prefer Adherence 10:2379\u20132385. https:\/\/doi.org\/10.2147\/PPA.S118396","journal-title":"Patient Prefer Adherence"},{"key":"1405_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11657-021-00889-7","volume":"16","author":"N Sagalla","year":"2021","unstructured":"Sagalla N, Lee R, Lyles K, Vognsen J, Col\u00f3n-Emeric C (2021) Extent of and reasons for osteoporosis medication non-adherence among veterans and feasibility of a pilot text message reminder intervention. Arch Osteoporos 16:21. https:\/\/doi.org\/10.1007\/s11657-021-00889-7","journal-title":"Arch Osteoporos"},{"key":"1405_CR21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00198-015-3116-z","volume":"26","author":"AD Cizmic","year":"2015","unstructured":"Cizmic AD, Heilmann RMF, Milchak JL, Riggs CS, Billups SJ (2015) Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial. Osteoporos Int 26:2131\u20132136. https:\/\/doi.org\/10.1007\/s00198-015-3116-z","journal-title":"Osteoporos Int"},{"key":"1405_CR22","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/jbmr.147","volume":"25","author":"K Kusamori","year":"2010","unstructured":"Kusamori K, Katsumi H, Abe M, Ueda A, Sakai R, Hayashi R, Hirai Y, Quan Y, Kamiyama F, Sakane T, Yamamoto A (2010) Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. J Bone Miner Res 25:2582\u20132591. https:\/\/doi.org\/10.1002\/jbmr.147","journal-title":"J Bone Miner Res"},{"key":"1405_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1248\/yakushi.13-00239","volume":"134","author":"H Katsumi","year":"2014","unstructured":"Katsumi H (2014) Development of a novel transdermal delivery system of alendronate, a nitrogen containing bisphosphonate, using a new type of hydrophilic patch and dissolving microneedle arrays. Yakugaku Zasshi 134:427\u2013431. https:\/\/doi.org\/10.1248\/yakushi.13-00239","journal-title":"Yakugaku Zasshi"},{"key":"1405_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124642","volume":"665","author":"A Ripolin","year":"2024","unstructured":"Ripolin A, Volpe-Zanutto F, Sabri AH, dos Santos VAB, Figueroba SR, Bezerra AAC, Vinicius Rodrigues Louredo B, Agustin Vargas P, McGuckin MB, Hutton ARJ, Larra\u00f1eta E, Franz-Montan M, Donnelly RF (2024) Transdermal delivery of bisphosphonates using dissolving and hydrogel-forming microarray patches: potential for enhanced treatment of osteoporosis. Int J Pharm 665:124642. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124642","journal-title":"Int J Pharm"},{"key":"1405_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3949\/ccjm.90a.22092","volume":"90","author":"S Keller","year":"2023","unstructured":"Keller S (2023) Making best use of bone turnover markers to monitor oral bisphosphonate therapy. Cleve Clin J Med 90:32\u201334. https:\/\/doi.org\/10.3949\/ccjm.90a.22092","journal-title":"Cleve Clin J Med"},{"key":"1405_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3949\/ccjm.90a.22002","volume":"90","author":"N Ashcherkin","year":"2023","unstructured":"Ashcherkin N, Patel AA, Algeciras-Schimnich A, Doshi KB (2023) Bone turnover markers to monitor oral bisphosphonate therapy. Cleve Clin J Med 90:26\u201331. https:\/\/doi.org\/10.3949\/ccjm.90a.22002","journal-title":"Cleve Clin J Med"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01405-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01405-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01405-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:21:43Z","timestamp":1766755303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01405-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1405"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01405-6","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"U. Stumpf: Has received honoraria for speaking at symposia and travel support from Eli Lilly, Alexion, Amgen, Theramex and UCB. P. Hadji:\u00a0Has\u00a0received study, educational and travel support from Amgen, Elli Lilly, Gedeon Richter, Procter and Gamble, STADA Arzneimittel AG, Theramex and UCB. K. Horas:\u00a0No conflicts of interest relevant to this work. J. Kyvernitakis:\u00a0No conflicts of interest relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted with the approval of the ethics committe of the University of Marburg. All participants gave a written informed consent at the start of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"99"}}